who is making retatrutide The next big shift in obesity care may not be surgery — it may be a weekly shot. Retatrutide, an investigational triple-action medicine, showed 28.3% average body-weight loss over 80 weeks in Retatrutide side effects: What to

However, if 5-Amino-1MQ also improves insulin sensitivity (as suggested in animal models), combined use particularly alongside insulin or sulfonylureas could theoretically increase the risk of low blood sugar to a clinically significant degree

But in Type 1 diabetes: They do not replace insulin They may promote ketogenesis Insulin dose reductions can trigger euglycemic DKA Appetite suppression and GI effects may worsen metabolic instability Type 1 diabetes management requires maintaining enough insulin not only for glucose control, but also to suppress ketone production

The plans are meeting that for those provider types broadly

Lancet 395 , 497506 (2020)